0001683168-24-001919.txt : 20240401 0001683168-24-001919.hdr.sgml : 20240401 20240329185251 ACCESSION NUMBER: 0001683168-24-001919 CONFORMED SUBMISSION TYPE: NT 10-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240401 DATE AS OF CHANGE: 20240329 EFFECTIVENESS DATE: 20240401 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOREGENX, INC. CENTRAL INDEX KEY: 0001593184 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROGRAMMING, DATA PROCESSING, ETC. [7370] ORGANIZATION NAME: 06 Technology IRS NUMBER: 462836541 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: NT 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-56345 FILM NUMBER: 24805126 BUSINESS ADDRESS: STREET 1: 7407 ZIEGLER ROAD CITY: CHATTANOOGA STATE: TN ZIP: 37421 BUSINESS PHONE: (866) 770-4067 MAIL ADDRESS: STREET 1: 7407 ZIEGLER ROAD CITY: CHATTANOOGA STATE: TN ZIP: 37421 FORMER COMPANY: FORMER CONFORMED NAME: FINDIT, INC. DATE OF NAME CHANGE: 20210219 FORMER COMPANY: FORMER CONFORMED NAME: ARTEMIS ENERGY HOLDINGS, INC. DATE OF NAME CHANGE: 20131127 NT 10-K 1 bioregenx_ext.htm REQUEST FOR EXTENSION

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SEC File Number 000-49819

FORM 12b-25

NOTIFICATION OF LATE FILING

(Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-CEN o N-CSR

For Period Ended: December 31, 2023

o Transition Report on Form 10-K

o Transition Report on Form 20-F

o Transition Report on Form 11-K

o Transition Report on Form 10-Q

For the Transition Period Ended: _______________

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:

PART I - REGISTRANT INFORMATION

	Full Name of Registrant:	BioRegenx, Inc.

	Former Name if Applicable:	Findit, Inc.

	Address of Principal Executive Office (Street and Number):	7407 Ziegler Road

	City, State and Zip Code:	Chattanooga, TN 37421

PART II - RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate) x

(a)

The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

☒

(b)

The subject annual report, semi-annual report, transition report on Forms 10-K, 20-F, 11-K, Form N-SAR, or portion thereof, will be filed on or before the 15th calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

(c)

The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III - NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-CEN, N-SAR, or the transition report portion thereof, could not be filed within the prescribed time period.

The registrant is unable to complete its audit and preparation of its Form 10-K for the period ended December 31, 2023 in a timely manner because of unanticipated delays.

PART IV - OTHER INFORMATION

(1)	Name and telephone number of person to contact in regard to this notification:

J.M. Walker & Associates

Attorneys at Law

(303) 850-7637

(Name)

(Area Code) (Telephone number)

(2)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months (or for such shorter) period that the registrant was required to file such reports) been filed? If answer is no, identify report(s): x Yes o No

(3)	Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof: o Yes x No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

BioRegenx, Inc. (formerly Findit, Inc.) has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date:	March 29, 2024		By:	/s/ William Resides
				Chief Executive Officer